In two secondary database analyses that monitored inpatient LOS for SUD over time, a decreasing trend was observed [ 25 , 44 ].
← all excerpts
Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review.
1
—
—